News and Comments

Biogen: A Fruitful Collaboration in Gene Therapy. A Small Gene Therapy Firm That You Should Know

  Tuesday, May 17, 2016


Seres Therapeutics Collaborates with Memorial Sloan Kettering Cancer Center to Improve Immunotherapy

  Friday, May 13, 2016

Seres Therapeutics (MCRB), is microbiome therapeutics platform company. It focuses on developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the natural state of bacterial diversity and function is imbalanced.  More...

Exelixis Again. The Road to Defeating DMD. Two New Important IPOs

  Monday, May 09, 2016


A Judge is Offended About False Claims Against Gilead. Good News from Regeneron

  Monday, May 02, 2016


The FDA Approval of Exelixis Drug Cabometyx™ Is Indeed Great News

  Tuesday, April 26, 2016

Congratulation.   More...

Nectar Therapeutics and Seattle Genetics at the AACR Meeting

  Tuesday, April 19, 2016

Meaningful Presentations  More...

Good News from Juno Therapeutics and from Abbvie. Disappointing News for Clovis Oncology

  Wednesday, April 13, 2016

Juno Therapeutics (JUNO) is due to receive a fee payment of $50 million from Celgene. The reason for this compensation is that Celgene has exercised its option to develop and commercialize Juno CD19 program outside North America and China.  More...

Theravance Biopharma Drug Vibativ Overcomes Serious Infections. See Also Juno Therapeutics In China

  Monday, April 11, 2016

Dealing With Bacterial Resistance To Antibiotics    More...

Human Longevity Firm Aims at Bringing the Missing Full Picture of Human Health

  Thursday, April 07, 2016


Gilead's Well Chosen New Acquisition Is Not the Last, It Is Just the Beginning

  Monday, April 04, 2016

Many in Wall Street have been anxious, sitting on fire while waiting to learn, which biotech company Gilead Sciences (GILD) would decide upon acquiring that would deepen and enhance its pipeline. In Today’s news, a firm called Nimbus Therapeutics, LLC today announced that it has signed a definitive agreement under which terms Gilead will acquire Nimbus Apollo, Inc., a Nimbus Therapeutics wholly-owned subsidiary. Important is that the acquisition includes the firm’s Acetyl-CoA Carboxylase (ACC) inhibitor program. The cost, which is around $1.2 billion will be given in an upfront payment of $400 million and an additional $800 million in development-related milestones over time. More...

Recent Postings



Agenus (AGEN Revlimid (lenolidamide) Valeant Pharmaceuticals International (VRX) Cytokinetics (CYTK) Ionis (IONS) Elan (ELN) REGULUS (RGLS) Agenus (AGEN) Sanofi-Aventis (SAN) Roche (ROCHE) Genentech Abbott Laboratories (ABT) Herceptin RenenxBio (RGNX) ImmunoGen (IMGN) Amgen (AMGN) Micromet (MITI) Spike Therapeutics (ONCE) Vertex (VRTX) KERYX (KERX) Advaxis (ADXS) ARCA (ABIO) Mirati Therapeutics (MRTX) Global Cell Therapeutics (GBT) Sanofi (SNA) Seattle Genetics (SGEN) Velcade (bortezomib) Dendreon (DNDN) SERES THERAPEUTICS (MCRB) Xoma (XOMA) Intrexon (XON) CompuGen (CGEN) MODERNA Theravance Bio Pharma (TBPH) Regeneron (REGN) Bellicum (BLCM) Human Longevity (HLI) ISIS (ISIS) ABBVIE (ABBV) Dynavax (DVAX) Multiple Myeloma ZALTRAP™ Anacor (ANAC) Ariad (ARIA) Gilead (GILD) GUARDIAN HEALTH Ridaforolimus Adaptimmune (ADAP) TOKAI (TKAOI) ARGOS (ARGS) Idenix (IDIX) SUNESIS PHARMACEUTICALS (SNSS) ACADIA (ACAD) Aimmune Therapeutics (AIMT) Rapamune Intercept (ICPT) Sangamo (SGMO) Alder Biopharmaceuticals (ALDR) Ziofpharm (ZIOP) Editas (EDIT) OSI (OSIP) Array Pharmaceuticals (ARRY) Tysabri VANDA (VNDA) Onyx (ONXX) Auspex (ASPX) BIOMARIN (BMRN) Zerenex Intermune (ITMN) Human Genome Sciences (HGSI) NEKTAR (NKTR)) Prolor Biotech (PBTH) Anadys (ANDS) Inovio (INO) Sarepta (SRPT) Trastuzumab-DM1 Vitae Pharmaceuticals (VTAE) C4 Therapeutics AERIE PHARMACEUTICALS Theravance (THRX) JUNO (JUNO) INNOVIVA (INVA) Galena (GALE) Endometrial Cancer Merck (MRK) Telaprevir ADVENTRIX (ANX) Prosensa (RNA) AstraZeneca (AZN) GlaxoSmithKline (GSK) Incyte (INCY) KITE (KITE) Jazz Pharmaceuticals (JAZZ) Biogen Idec (BIIB) galapagos (GLPG) NANTKWEST (NK) NOVOCURE (NVCR) SYNTA (SNTA) Benlysta (belimumab) Bristol-Myers Squibb (BMY) Exelixis (EXEL) Alnylam (ALNY) Roche (RHHBY) PTC Therapeutics (PTCT) Illumina (ILMN) AGOS (ARGS) Sequenom (SQNM) HALOZYME (HALO) Biocryst (BCRX) CRISPR Therapeutics (CRSP) Pluristem (PSTI) IDERA (IDRA) Sanofi (SNY)